YOSHIO YAMAOKA to Drug Therapy, Combination
This is a "connection" page, showing publications YOSHIO YAMAOKA has written about Drug Therapy, Combination.
Connection Strength
1.446
-
Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam. Helicobacter. 2024 Nov-Dec; 29(6):e13149.
Score: 0.173
-
Revolution of Helicobacter pylori treatment. J Gastroenterol Hepatol. 2024 Jun; 39(6):1016-1026.
Score: 0.166
-
Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver. 2019 09 15; 13(5):483-497.
Score: 0.122
-
Helicobacter pylori therapy and clinical perspective. J Glob Antimicrob Resist. 2018 09; 14:111-117.
Score: 0.110
-
An East-Asian-type cagA Helicobacter pylori Infected Patient with Clinical Manifestation of Gastric Ulcer. Acta Med Indones. 2016 Oct; 48(4):307-313.
Score: 0.099
-
Strategy for the treatment of Helicobacter pylori infection. Curr Pharm Des. 2014; 20(28):4489-500.
Score: 0.082
-
Helicobacter pylori infection in Japan. Expert Rev Gastroenterol Hepatol. 2013 Jan; 7(1):35-40.
Score: 0.076
-
Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol. 2012 Apr; 46(4):297-301.
Score: 0.073
-
Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol. 2009 Nov; 24(11):1725-32.
Score: 0.061
-
Virulence factor genotypes of Helicobacter pylori affect cure rates of eradication therapy. Arch Immunol Ther Exp (Warsz). 2009 Jan-Feb; 57(1):45-56.
Score: 0.058
-
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
Score: 0.054
-
A report card to grade Helicobacter pylori therapy. Helicobacter. 2007 Aug; 12(4):275-8.
Score: 0.052
-
One- or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut. 2007 Jul; 56(7):1021-3; author reply 1022-3.
Score: 0.052
-
Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial). Sci Rep. 2024 04 18; 14(1):8986.
Score: 0.042
-
Cut-off value of clarithromycin resistance in the treatment of Helicobacter pylori infection: how low is low? Gut. 2024 01 05; 73(2):374-375.
Score: 0.041
-
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). PLoS One. 2023; 18(11):e0294403.
Score: 0.041
-
Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
Score: 0.039
-
Prevalence and Pattern of Antibiotic Resistant Strains of Helicobacter Pylori Infection in ASEAN Asian Pac J Cancer Prev. 2018 May 26; 19(5):1411-1413.
Score: 0.028
-
Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
Score: 0.027
-
Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Helicobacter pylori Infection in the Dominican Republic. Am J Trop Med Hyg. 2017 May; 96(5):1050-1059.
Score: 0.025
-
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
Score: 0.012
-
Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. J Gastroenterol Hepatol. 1998 Jul; 13(7):732-7.
Score: 0.007
-
Regression of atypical lymphoid hyperplasia after eradication of Helicobacter pylori. J Gastroenterol. 1997 Aug; 32(4):543-7.
Score: 0.007